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Abstract
Neuronal nitric oxide synthase (nNOS) is a key enzyme for nitric oxide production in neuronal
tissues and contributes to the spinal central sensitization in inflammatory pain. However, the role
of nNOS in neuropathic pain remains unclear. The present study combined a genetic strategy with
a pharmacologic approach to examine the effects of genetic knockout and pharmacologic inhibition
of nNOS on neuropathic pain induced by unilateral fifth lumbar spinal nerve injury in mice. In
contrast to wildtype mice, nNOS knockout mice failed to display nerve injury-induced mechanical
hypersensitivity. Furthermore, either intraperitoneal (100 mg/kg) or intrathecal (30 µg/5  µl)
administration of L-NG-nitro-arginine methyl ester, a nonspecific NOS inhibitor, significantly
reversed nerve injury-induced mechanical hypersensitivity on day 7 post-nerve injury in wildtype
mice. Intrathecal injection of 7-nitroindazole (8.15 µg/5  µl), a selective nNOS inhibitor, also
dramatically attenuated nerve injury-induced mechanical hypersensitivity. Western blot analysis
showed that the expression of nNOS protein was significantly increased in ipsilateral L5 dorsal root
ganglion but not in ipsilateral L5 lumbar spinal cord on day 7 post-nerve injury. The expression of
inducible NOS and endothelial NOS proteins was not markedly altered after nerve injury in either
the dorsal root ganglion or spinal cord. Our findings suggest that nNOS, especially in the dorsal
root ganglion, may participate in the development and/or maintenance of mechanical
hypersensitivity after nerve injury.
Background
Considerable evidence has shown that nitric oxide (NO)
acts as an important mediator in the peripheral and cen-
tral nervous systems and functions in a wide variety of
physiologic and pathophysiologic processes, such as neu-
rotransmission, synaptic plasticity, neuroprotection, neu-
rotoxicity, and pathologic pain [1-3]. NO is synthesized
by three well-characterized isoforms of NO synthase
(NOS): neuronal NOS (nNOS), endothelial NOS
(eNOS), and inducible NOS (iNOS). Under pathologic
conditions, these three NOS isoforms could be upregu-
lated in nervous tissues [4-6]. Thus, the pathophysiologic
functions of NO in the nervous system may be regulated
by the expression and activity of one, two, or all three
NOS isoforms.
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Neuronal NOS is expressed in the neurons and produces
predominantly NO in neuronal tissues [1]. The contribu-
tion of nNOS-synthesized NO to nociceptive processing
has been characterized in several inflammatory pain mod-
els [2]. Peripheral inflammation induced by formalin or
complete Freund's adjuvant increases nNOS (but not
eNOS or iNOS) expression in the spinal cord [5,7,8] and
dorsal root ganglion (DRG) [9]. Systemic or intrathecal
administration of nonspecific NOS inhibitors or selective
nNOS inhibitors reduces the exaggerated pain in animals
after formalin-, carrageenan-, or complete Freund's adju-
vant-induced peripheral inflammation [5,9-15]. Moreo-
ver, targeted disruption of the nNOS gene attenuates
carrageenan- and complete Freund's adjuvant-induced
thermal and mechanical pain hypersensitivity in mice
[5,15], although nNOS knockout mice were reported to
display intact formalin-induced nociceptive behaviors
[16]. These observations indicate that nNOS at the spinal
cord level may play a critical role in the central mecha-
nism of inflammatory pain.
In addition to inflammation, peripheral nerve injury also
causes clinically relevant persistent or chronic pain.
Although nerve injury-induced neuropathic pain has
some unique characteristics in regard to pathogenesis,
central mechanisms, and treatment compared to inflam-
matory pain [17], these two types of persistent pain may
share some intracellular signaling pathways in their cen-
tral mechanisms [18]. However, the exact role of nNOS in
neuropathic pain, especially at the spinal cord level, is
unclear. Peripheral nerve injury increased expression of
both mRNA and protein for nNOS in the DRG, but not in
spinal cord [19-22]. Although systemic or spinal treat-
ment with specific and nonspecific nNOS inhibitors has
been shown to block neuropathic pain [23-27], two inves-
tigators reported that systemic or intrathecal administra-
tion of specific and nonspecific nNOS inhibitors had no
effect on nerve injury-induced allodynia [19,28]. It is evi-
dent that these pharmacologic results are conflicting. In
the current study, by combining a genetic strategy (using
nNOS knockout mice) with a pharmacologic approach
(using selective and nonspecific nNOS inhibitors), we
determined the functional role of nNOS in chronic neuro-
pathic pain induced by L5 spinal nerve injury in mice. In
addition, we examined the expression of nNOS, as well as
iNOS and eNOS, in DRG and spinal cord after spinal
nerve injury.
Results
Effect of nNOS knockout on spinal nerve injury-induced 
mechanical hypersensitivity
Consistent with our previous studies [29,30], the fifth
lumbar spinal nerve injury produced long-term mechani-
cal hypersensitivity on the ipsilateral hind paw in
wildtype (WT) mice (n = 12). The application of 0.24 mN
(low intensity) and 4.33 mN (moderate intensity) von
Frey filaments to the plantar side of the hind paw ipsilat-
eral to the nerve injury elicited significant increases in paw
withdrawal frequencies, as compared to pre-injury base-
line values, a behavioral indication of mechanical hyper-
sensitivity. This mechanical hypersensitivity appeared on
day 3, reached a peak level between days 5 and 7, and per-
sisted for at least 17 days post-nerve injury (Fig. 1A, B).
The baseline withdrawal responses to mechanical stimuli
were similar in WT and nNOS knockout mice (Fig. 1A, B),
but nNOS knockout mice (n  = 10) did not display
mechanical hypersensitivity following spinal nerve injury.
Compared to the baseline level, no significant increases in
withdrawal frequencies were observed in response to
mechanical stimuli in the knockout mice (P > 0.05; Fig.
1A, B). As expected, no significant changes in paw with-
drawal responses to mechanical stimuli were seen on the
contralateral hind paw in either WT or nNOS knockout
mice following spinal nerve injury (Fig. 1A, B).
Effect of targeted disruption of the nNOS gene on nerve  injury-induced neuropathic pain Figure 1
Effect of targeted disruption of the nNOS gene on nerve 
injury-induced neuropathic pain. L5 spinal nerve injury pro-
duced a significant increase in paw withdrawal frequencies in 
response to 0.24 mN (low intensity) (A) and 4.33 mN (mod-
erate intensity) (B) mechanical stimuli on the ipsilateral (ipsi) 
side in wildtype (WT) mice. The nNOS knockout (KO) mice 
displayed impaired mechanical pain hypersensitivity on the 
ipsilateral side (A, B). No significant changes in paw with-
drawal frequencies were seen on the contralateral (contral) 
side after L5 spinal nerve injury in either WT or nNOS KO 
mice. **P < 0.01 vs corresponding time points in the WT 
mice.
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Effect of systemic administration of a nonspecific NOS 
inhibitor on nerve injury-induced mechanical 
hypersensitivity
We examined the effect of systemic inhibition of NOS on
nerve injury-induced mechanical pain hypersensitivity in
WT mice. A nonspecific NOS inhibitor, L-NG-nitro-
arginine methyl ester (L-NAME) and its inactive enanti-
omer, D-NAME, were administered intraperitoneally on
day 7 post-nerve injury. Intraperitoneal injection of D-
NAME failed to produce a significant effect on nerve
injury-induced increases in ipsilateral paw withdrawal fre-
quencies in response to low- and moderate-intensity
mechanical stimuli (n = 9; Fig. 2A, B). However, intraperi-
toneal injection of L-NAME significantly reversed nerve
injury-evoked mechanical hypersensitivity on the ipsilat-
eral side (n = 11; Fig. 2A, B). The average paw withdrawal
frequencies to low- and moderate-intensity mechanical
stimuli after administration of L-NAME were reduced by
58% and 48%, respectively, compared to the values in the
D-NAME-treated groups (P < 0.01). As expected, neither
L-NAME nor D-NAME at the doses used affected contral-
ateral paw withdrawal responses to mechanical stimuli
(Fig. 2C, D).
Effect of intrathecal injection of nonspecific and specific 
nNOS inhibitors on nerve injury-induced mechanical 
hypersensitivity
To define the role of NOS, especially nNOS, in neuro-
pathic pain at the spinal cord level, we next examined the
effect of intrathecally injected L-NAME or 7-nitroindazole
(7-NI), a specific nNOS inhibitor, on nerve injury-
induced mechanical hypersensitivity 7 days after spinal
nerve injury in WT mice. In D-NAME-treated (n = 10) or
vehicle (20% DMSO)-treated (n = 8) groups, withdrawal
frequencies to low- and moderate-intensity mechanical
stimuli applied to the ipsilateral hindpaw were signifi-
cantly higher than those at baseline (P < 0.01; Figs. 3A, B,
and 4A, B). In contrast, intrathecal injection of L-NAME
significantly reversed nerve injury-induced mechanical
hypersensitivity (n = 12; Fig. 3A, B). Compared to those in
D-NAME-treated animals, paw withdrawal frequencies in
response to low- and moderate-intensity mechanical stim-
uli were reduced by 66% and 47%, respectively (P < 0.01).
Importantly, intrathecal 7-NI (n = 7) produced inhibitory
effects similar to L-NAME on the nerve injury-induced
mechanical pain hypersensitivity (Fig. 4A, B). Paw with-
drawal frequencies were reduced by 56% and 43% of the
values in the vehicle-treated groups in response to low-
and moderate-intensity mechanical stimuli, respectively
(P  < 0.05). Neither 7-NI nor L-NAME altered the
Effect of intraperitoneal (i.p.) injection of L-NAME or D-NAME on mechanical pain hypersensitivity on day 7 after L5 spinal  nerve injury in WT mice Figure 2
Effect of intraperitoneal (i.p.) injection of L-NAME or D-NAME on mechanical pain hypersensitivity on day 7 after L5 spinal 
nerve injury in WT mice. Paw withdrawal responses to 0.24 mN (A and C) and 4.33 mN (B and D) mechanical stimuli on the 
ipsilateral (A and B) and contralateral (C and D) sides. *P < 0.05, **P < 0.01 vs the corresponding baseline. ##P < 0.01 vs the 
post-drug, D-NAME-treated group.
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responses to mechanical stimuli on the contralateral
hindpaw (Figs. 3C, D, and 4C, D).
Effect of spinal nerve injury on nNOS expression in the 
DRG and spinal cord
Finally, we examined whether peripheral spinal nerve
injury altered the expression of nNOS, iNOS, or eNOS in
the DRG and spinal cord of WT mice. We found that
nNOS in the ipsilateral (but not in the contralateral) fifth
DRG was increased after the L5 spinal nerve injury (Fig. 5).
Quantification showed that nNOS protein levels in the
ipsilateral DRG tissues on day 7 post-nerve injury (n = 16
mice) were 1.6-fold greater than those from naïve mice (n
= 16 mice; P < 0.05) and 1.4-fold more than those on day
7 post-sham surgery (n = 16 mice; P < 0.05). Interestingly,
the amount of nNOS protein in the ipsilateral and con-
tralateral L5 dorsal horn on day 7 post-nerve injury (n = 16
mice) was similar to that from naïve mice (n = 16 mice)
and mice 7 days after sham surgery (n = 16 mice; P > 0.05;
Fig. 6). In addition, L5 spinal nerve injury did not change
the expression level of nNOS in either ipsilateral or con-
tralateral L4 DRG and L4 dorsal horn at day 7 post-nerve
injury (data not shown). The expression levels of eNOS
and iNOS in the DRG and spinal cord were not markedly
different on day 7 post-nerve injury than those of the
sham groups or naïve mice (n = 16 mice/group;P > 0.05;
Figs. 5, 6).
Discussion
The present study provides the first evidence that targeted
disruption of the nNOS gene significantly attenuates
nerve injury-induced mechanical hypersensitivity. Moreo-
ver, nerve injury-induced mechanical hypersensitivity in
WT mice was significantly inhibited by systemic and
intrathecal administration of L-NAME and by intrathecal
treatment with 7-NI. Peripheral nerve injury increased the
expression of nNOS in the DRG, although it did not alter
the expression of nNOS in the spinal cord. Our findings
suggest that nNOS, especially in the DRG, may play a crit-
ical role in nerve injury-induced mechanical hypersensi-
tivity.
Conflicting pharmacological evidence has been reported
regarding the effects of systemic or spinal treatment with
specific or non-specific NOS inhibitors on neuropathic
pain. Meller et al. [24] first reported that intrathecal
administration of L-NAME (20 nmol) on day 3 after loose
ligation of the sciatic nerve blocked the thermal hyperal-
gesia in rats for a period of 2 h. A subsequent study also
demonstrated that injecting 3-bromo-7-NI (a specific
Effect of intrathecal (i.th.) injection of L-NAME or D-NAME on mechanical pain hypersensitivity on day 7 after L5 spinal nerve  injury in WT mice Figure 3
Effect of intrathecal (i.th.) injection of L-NAME or D-NAME on mechanical pain hypersensitivity on day 7 after L5 spinal nerve 
injury in WT mice. Paw withdrawal responses to 0.24 mN (A and C) and 4.33 mN (B and D) mechanical stimuli on the ipsilat-
eral (A and B) and contralateral (C and D) sides. **P < 0.01 vs the corresponding baseline. ##P < 0.01 vs the post-drug, D-
NAME-treated group.
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nNOS inhibitor, 10 mg/kg) intramuscularly into the mid-
thigh region daily for 7 days beginning on day 7 post-sur-
gery significantly alleviated nerve injury-induced thermal
hyperalgesia from weeks 5 and 6 onward in rats [25].
Yoon et al. [26] further showed that both mechanical and
cold allodynia induced by tight ligature of the left L5 and
L6 spinal nerves were dose dependently suppressed during
the maintenance phases (1 to 3 weeks post-ligature) by
intraperitoneal L-NAME (10, 50, 100, and 200 µM/kg). In
support of these findings, our pharmacological study
showed that spinal nerve injury-induced mechanical
hypersensitivity in mice could be dramatically attenuated
by systemically (100 mg/kg) and intrathecally (30 µg)
injected L-NAME and by intrathecally injected 7-NI (8.15
µg) on day 7 post-nerve injury (Figs. 2, 3, 4). Interestingly,
Yamamoto and Shimoyama [27] found that the develop-
ment of thermal hyperesthesia evoked by sciatic nerve
constriction injury was significantly delayed by intrathe-
cal pre-treatment (10 min before injury), but not post-
treatment (15 min after injury), with NOS inhibitors Nω-
nitro-L-arginine (30 µg) and L-NAME (100 µg). However,
Pan et al. [28] reported that allodynia induced by tight
ligation of the left L5 and L6 spinal nerves was not affected
by intrathecal injection of either NG-monomethyl-
arginine (a non-specific NOS inhibitor, 30 µg) or 1-(2-tri-
fluoromethylphenyl) imidazole (a nNOS inhibitor, 30
µg) at the third or fourth week post-nerve injury. Addi-
tionally, Luo et al. [19] observed that neither pre-surgical
(once daily for 6 days beginning 30 min before surgery)
nor post-surgical (days 11 through 13) 7-NI (50 mg/kg)
given subcutaneously or intraperitoneally affected the
development or maintenance of tactile allodynia evoked
by tight ligature of the left L5 and L6 spinal nerves in rats.
The reason for the discrepancies among these pharmaco-
logical studies is unclear but may be related to the drug
potency, delivery method, dose, and administration
times. It is worth noting that only one dose of a nonspe-
cific or specific nNOS inhibitor was administered by Luo
et al. [19] and Pan et al [28]. It is possible that the higher
doses used in these two studies might have had a signifi-
cant inhibitory effect on nerve injury-induced neuro-
pathic pain. Our nNOS knockout mouse study clearly
demonstrated that deficiency of nNOS significantly
blunted spinal nerve injury-induced mechanical hyper-
sensitivity (Fig. 1). In addition, nNOS knockout mice
exhibited impaired nerve injury-induced thermal hyper-
Effect of intrathecal injection of 7-NI on mechanical pain hypersensitivity on day 7 after L5 spinal nerve injury in WT mice Figure 4
Effect of intrathecal injection of 7-NI on mechanical pain hypersensitivity on day 7 after L5 spinal nerve injury in WT mice. Paw 
withdrawal responses to 0.24 mN (A and C) and 4.33 mN (B and D) mechanical stimuli on the ipsilateral (A and B) and contral-
ateral (C and D) sides. *P < 0.05, **P < 0.01 vs the corresponding baseline. ##P < 0.01 vs the post-drug, vehicle-treated group.
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sensitivity (data not shown). Although it has been
reported that spinal eNOS is upregulated in nNOS KO
mice [5], it appears that this upregulation does not fully
compensate for nNOS function in neuropathic pain.
Thus, our genetic knockout and pharmacologic studies
support the notion that nNOS, particularly at the spinal
cord level, may contribute to the mechanisms that under-
lie the development and/or maintenance of neuropathic
pain.
Peripheral nerve injury insult has distinct effects on nNOS
expression in the DRG and dorsal horn. Under normal
conditions, the DRG contains only a few neurons that
exhibit nNOS labeling, the majority of which are very
small, whereas spinal dorsal horn exhibits intense nNOS
labeling in several neuronal types, especially in the super-
ficial dorsal horn [20]. It has been reported that constric-
tion of the common sciatic nerve in rats increased nNOS
expression in the ipsilateral L4-L6 DRG, but not in spinal
Expression of nNOS, eNOS, and iNOS in the ipsilateral (I)  and contralateral (C) dorsal horn of L5 spinal cord in naïve  WT mice and WT mice 7 days after sham surgery or L5 spi- nal nerve injury Figure 6
Expression of nNOS, eNOS, and iNOS in the ipsilateral (I) 
and contralateral (C) dorsal horn of L5 spinal cord in naïve 
WT mice and WT mice 7 days after sham surgery or L5 spi-
nal nerve injury. (A) Representative examples of Western 
blots. β-actin was used as a loading control. (B-D) Statistical 
summary of the densitometric analysis expressed relative to 
the contralateral side in naïve mice.
e
ȕ
ȕ
ȕ
CICIC I
Naïve Sham SNI A
e
e
e
B
e
e
e
e
C
e
e
e
ï e
D
Expression of nNOS, eNOS, and iNOS in the ipsilateral (I)  and contralateral (C) L5 dorsal root ganglia in naïve WT mice  and WT mice 7 days after sham surgery or L5 spinal nerve  injury Figure 5
Expression of nNOS, eNOS, and iNOS in the ipsilateral (I) 
and contralateral (C) L5 dorsal root ganglia in naïve WT mice 
and WT mice 7 days after sham surgery or L5 spinal nerve 
injury. (A) Representative examples of Western blots. β-
actin was used as a loading control. (B-D) Statistical summary 
of the densitometric analysis expressed relative to the con-
tralateral side in naïve mice. *P < 0.05 vs the corresponding 
side in naïve mice or the sham-operated group.
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segments L4-L6 [20]. The increased level of nNOS protein
in the DRG was seen in the small, medium, and large cell
bodies [20]. Likewise, tight, unilateral ligature of the rat L5
and L6 spinal nerves increased nNOS mRNA in ipsilateral
L5/6 DRG neurons, but not in dorsal horn, beginning 1 day
after nerve ligation and lasting for at least 13 weeks [19].
A corresponding increase in DRG (but not spinal cord)
nNOS protein was also observed and localized mainly to
small and occasionally medium-sized sensory neurons
[19,21]. Consistent with these findings in rats, our study
showed that unilateral injury of the fifth spinal nerve in
mice also increased expression of nNOS protein in the
ipsilateral fifth DRG, but not in dorsal horn. An increase
in the DRG NOS catalytic activity and a decrease in spinal
NOS catalytic activity have been reported following
peripheral nerve injury [20,22]. The evidence described
above indicates that peripheral nerve injury up-regulates
expression and activity of nNOS in small DRG neurons
and down-regulates its expression and activity in the spi-
nal cord. Such adaptations suggest that the increased
nNOS in the DRG may be involved in the mechanism
underlying the development and/or maintenance of neu-
ropathic pain. It has been demonstrated that intrathecally
administered agents can directly affect activities of DRG
proteins in pain processing in addition to affecting activi-
ties of these proteins in spinal cord neurons [31]. It is very
likely that the pharmacologic effects of specific and non-
specific NOS inhibitors in the present study were medi-
ated through their actions on the DRG nNOS, although
our data could not exclude their effects on spinal cord
nNOS.
Consistent with previous reports [5,31,32], our study
detected basal expression of eNOS and iNOS proteins in
the spinal cord and DRG of mice under normal condi-
tions. However, the expression of neither was altered in
the spinal cord or DRG on day 7 post-nerve injury. It
should be noted that we did not examine iNOS expression
at the ligature site or at other time points post-nerve
injury. Previous studies showed that local expression of
iNOS was induced at 3 days and persisted for at least 26
days at the constriction and distal sites following chronic
constriction partial nerve injury [33-36]. Systemic and
topical administration of specific or non-specific iNOS
inhibitors reversed nerve hyperaemia proximal and distal
to the constriction [35]. Targeted disruption of the iNOS
gene slowed Wallerian degeneration of myelinated fibers
and delayed regeneration of myelinated and smaller cal-
iber fibers in a chronic constriction partial nerve injury
model [35]. Slowed nerve degeneration is associated with
normal initiation but delayed expression of neuropathic
pain [35], suggesting that local induction of iNOS expres-
sion may be important in the pathogenesis of nerve
injury-induced neuropathic pain. Thus, our data do not
exclude the possibility that iNOS at the ligature site might
play a role in the development of neuropathic pain.
The mechanism by which DRG NOS-synthesized NO con-
tributes to the development and/or maintenance of neu-
ropathic pain is unclear. A gaseous molecular, NO diffuses
out from the DRG neurons or primary afferent terminals
and stimulates guanylyl cyclase in neighboring DRG or
dorsal horn neurons to form cyclic guanosine monophos-
phate (cGMP) [2]. cGMP activates several intracellular
processes, including cGMP-dependent protein kinase
(PKG), ion channels, and phosphodiesterases (PDEs)
[37]. PKG is present in the small DRG neurons and the
superficial dorsal horn [38,39]. Sung et al. [40] showed
that PKG was activated in peripheral terminals of the DRG
neurons and retrogradely transported to the DRG after
peripheral nerve injury and inflammation; however,
intrathecal injection of a PKG inhibitor did not affect
nerve injury-induced mechanical hypersensitivity [41].
Interestingly, intraplantar injection of a PDE-5 inhibitor
significantly reduced mechanical hypersensitivity in dia-
betic neuropathy. This effect could be reversed by inhibi-
tion of NOS and guanylyl cyclase [42]. In addition, NO
modulates the DRG Ca2+ and Na+ channels via cGMP-
dependent pathways [43-45]. Therefore, it is very likely
that DRG NOS-synthesized NO contributes to the mecha-
nism that underlies the development and/or maintenance
of neuropathic pain by activating PDEs and/or ion chan-
nels, but not by activating PKG, in the DRG and spinal
cord.
In summary, we have provided genetic evidence that the
deficiency of nNOS protein impairs mechanical hypersen-
sitivity during the development and maintenance of neu-
ropathic pain. Pharmacologic studies further
demonstrated that systemic or spinal administration of
specific and non-specific nNOS inhibitors attenuates
nerve injury-induced mechanical hypersensitivity. Moreo-
ver, peripheral nerve injury up-regulates nNOS expression
in the DRG but not in the spinal cord. These findings sug-
gest that the DRG nNOS may play a role in the mecha-
nism underlying neuropathic pain.
Methods
Animal preparation
The nNOS knockout mice (C57BL/6J background) were
purchased from Jackson Laboratories (Bar Harbor, ME,
USA), cross-bred with C57BL/6J WT mice in our labora-
tory, and kept on a standard 12-h light/dark cycle, with
water and food pellets available ad libitum. The genomic
status of each mouse was checked with the use of reverse
transcriptase-PCR and Western blotting [5]. Male and
female nNOS knockout mice are viable and fertile with
normal appearance, as described before [5,46]. Male mice
weighing 25–30 g were used, and the WT littermates wereMolecular Pain 2007, 3:29 http://www.molecularpain.com/content/3/1/29
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used as controls. To minimize intra- and inter-individual
variability of behavioral outcome measures, animals were
trained for 1–2 days before behavioral testing was per-
formed. Animal experiments were conducted with the
approval of the Animal Care and Use Committee at Johns
Hopkins University and were consistent with the ethical
guidelines of the National Institutes of Health and the
International Association for the Study of Pain. All efforts
were made to minimize animal suffering and to reduce
the number of animals used.
Experimental drugs
L-NAME and D-NG-nitro-arginine methyl ester (D-
NAME) were purchased from Alexis Biochemicals (San
Diego, CA, USA). 7-NI was purchased from Calbiochem
Biosciences (La Jolla, CA, USA). 7-NI was dissolved in
20% dimethylsulfoxide (DMSO); all other drugs were dis-
solved in saline.
Intrathecal injection
Intrathecal injection was performed under brief isoflurane
(1.5%) anesthesia to reduce stress, as described previously
[5]. Briefly, a 30-gauge, 0.5-inch needle connected to a 10-
µl syringe was inserted into one side of the L5 or L6 spinous
process at an angle of approximately 20° above the verte-
bral column and slipped into the groove between the
spinous and transverse processes. While the angle of the
syringe was decreased to approximately 10°, the needle
was moved carefully forward to the intervertebral space. A
tail flick indicated that the tip of the needle was inserted
into the subarachnoid space. Total volume of the injected
solution was 5 µl. Mice were completely recovered (that is,
were spontaneously active) within 3–5 min after injec-
tion.
Spinal nerve injury-induced neuropathic pain model in 
mice
The spinal nerve injury model was produced in mice as
described previously [30]. In brief, the mice were anesthe-
tized with isoflurane and placed in a prone position. The
left paraspinal muscles were separated from the spinous
processes at the L4-S2 levels under aseptic conditions, and
the left L5 spinal nerve was isolated, tightly ligated with a
silk thread (7-0), and transected just distal to the ligature.
In a control sham group, the surgical procedure was iden-
tical to that described above, except that the left L5 spinal
nerve was not ligated and transected. The mice were
returned to their cages and observed for any signs of
motor deficits. None of the mice showed motor dysfunc-
tion after surgery. Behavioral tests described below were
performed 1 day before spinal nerve injury and 3, 5, 7, 9,
13, and 17 days after spinal nerve injury.
To examine the effects of systemic administration of NOS
inhibitors on the maintenance of L5 spinal nerve injury-
induced mechanical hypersensitivity, WT mice received
intraperitoneal injection of L-NAME (100 mg/kg), D-
NAME (100 mg/kg), or saline on day 7 after spinal nerve
injury. To further define the role of NOS at the spinal cord
level in spinal nerve injury-induced mechanical hypersen-
sitivity, the WT mice received an intrathecal injection of L-
NAME (30 µg/5 µl), D-NAME (30 µg/5 µl), 7-NI (8.15 µg/
5 µl), or vehicle (20% DMSO or saline, 5 µl) on day 7 after
spinal nerve injury. Behavioral tests were performed as
described below 1 day before spinal nerve injury, 1 h
before drug administration, and 20 min after drug admin-
istration on day 7 post-nerve injury. The doses and dura-
tion of drug administration were based on our previous
studies and those of others [5,14,47,48].
Behavioral testing
To measure paw withdrawal responses to repeated
mechanical stimuli, each mouse was placed in a Plexiglas
chamber on an elevated mesh screen. Two calibrated von
Frey monofilaments (0.24 and 4.33 mN; Stoelting Co.,
Wood Dale, IL, USA) were used. Each von Frey filament
was applied to the hind paw for approximately 1 sec, and
each stimulation was repeated 10 times to both hind
paws. The occurrence of paw withdrawal in each of these
10 trials was expressed as a percent response frequency
[(number of paw withdrawals/10 trials) × 100 = %
response frequency], and this percentage was used as an
indication of the amount of paw withdrawal. Experiment-
ers were blinded to mouse genotype and drug assignment.
Western blot analysis
WT mice were sacrificed by decapitation on day 7 after spi-
nal nerve injury or sham surgery. Naïve mice were used as
controls. The fourth and fifth lumbar ipsilateral and con-
tralateral DRGs and spinal dorsal horns were removed. All
tissues were quickly frozen in liquid nitrogen and stored
at -80°C for later use. Because of the small size of the uni-
lateral fifth DRG and dorsal horn, the DRGs from four
mice and dorsal horns from two mice were pooled
together to obtain enough protein for Western blot analy-
sis. Frozen tissues were homogenized in buffer (10 mM
Tris-HCl, 5 mM MgCl2, 2 mM EGTA, 1 mM phenylmeth-
ylsulfonyl fluoride, 1 µM leupeptin, 2 µM pepstatin A, 1
mM dithiothreitol). The crude homogenate was centri-
fuged at 4°C for 15 min at 700 × g. The supernatants (100
µg) were heated for 5 min at 98°C and then loaded onto
4% stacking/7.5% separating SDS-polyacrylamide gels.
The proteins were electrophoretically transferred onto
nitrocellulose membrane, blocked with 3% nonfat dry
milk, and subsequently incubated overnight at 4°C with
polyclonal rabbit anti-nNOS antibody (1:1,000, BD
Transduction Laboratories, San Diego, CA, USA), polyclo-
nal rabbit anti-eNOS antibody (1:1,000, BD Transduc-
tion), polyclonal rabbit anti-iNOS antibody (1:1,000, BD
Transduction), or monoclonal mouse anti-β-actin anti-Molecular Pain 2007, 3:29 http://www.molecularpain.com/content/3/1/29
Page 9 of 10
(page number not for citation purposes)
body (1:3,000, Sigma, St. Louis, MO, USA). β-actin was
used as a loading control. The proteins were detected with
horseradish peroxidase-conjugated anti-rabbit or anti-
mouse secondary antibodies and visualized by chemilu-
minescence reagents provided with the ECL kit (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA) and
exposure to film. The intensity of blots was quantified
with densitometry. The blot density from the contralateral
DRG or dorsal horn in the naïve mice was set as 100%.
The relative density values of the ipsilateral DRG or dorsal
horn in the naïve mice and from ipsilateral or contralat-
eral DRG or dorsal horn in the spinal nerve-injured or
sham-operated group were determined by dividing the
optical density values from these groups by a value from
the contralateral DRG or dorsal horn in the naïve mice.
Statistical analysis
Data from the behavioral tests and Western blots were
expressed as mean ± SEM and analyzed with a one-way or
two-way analysis of variance (ANOVA). When ANOVA
showed significant differences, pairwise comparisons
between means were tested by the post hoc Tukey
method. A pairwise t-test was used to determine the signif-
icant differences of means for comparisons between two
groups. Significance was set at P < 0.05. All statistical anal-
yses were performed using the SigmaStat statistical soft-
ware.
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